Drug Type Fluorophore-conjugated therapeutics |
Synonyms ONM-100, ONM-100 DS |
Target- |
Mechanism Diagnostic dye |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization OncoNano Medicine, Inc.Startup |
Active Organization OncoNano Medicine, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (US) |
Start Date17 Apr 2024 |
Sponsor / Collaborator |
Start Date13 Apr 2022 |
Sponsor / Collaborator OncoNano Medicine, Inc.Startup |
Start Date30 Nov 2021 |
Sponsor / Collaborator OncoNano Medicine, Inc.Startup |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Secondary malignant neoplasm of peritoneum | Phase 2 | US | OncoNano Medicine, Inc.Startup | 30 Nov 2021 |
Breast Cancer | Phase 2 | US | OncoNano Medicine, Inc.Startup | 09 Aug 2019 |
Colorectal Cancer | Phase 2 | US | OncoNano Medicine, Inc.Startup | 09 Aug 2019 |
Non-Small Cell Lung Cancer | Phase 2 | US | OncoNano Medicine, Inc.Startup | 09 Aug 2019 |
Ovarian Cancer | Phase 2 | US | OncoNano Medicine, Inc.Startup | 09 Aug 2019 |
Prostatic Cancer | Phase 2 | US | OncoNano Medicine, Inc.Startup | 09 Aug 2019 |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | US | OncoNano Medicine, Inc.Startup | 09 Aug 2019 |
Transitional Cell Carcinoma | Phase 2 | US | OncoNano Medicine, Inc.Startup | 09 Aug 2019 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 40 | rfbfctrbwq(skztcwrrfj) = Treatment-related, non-anaphylactic infusion reactions occurred in 26% of patients and were transient, with a median duration of 9 minutes. gdrwcjnakl (mqmhuzvimk ) | Positive | 31 May 2023 |